U.S. Court of Appeals … UPHOLDS FDA BAR to overturn disapproval of device
CYTX lost a U.S. appeals court bid to overturn the FDA initial rejection of 2 medical devices that use fat as a source of stem-cell therapy.
The Bottom Line: I believe - it was a long shot anyway! Status quo is maintained as CYTX is still pursuing the primary path to market - a PMA filing to capture the market opportunity they wanted.
CYTX had closed at $2.77 on Wednesday and is down -$0.01 or -0.36%.
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.